People with ulcerative colitis, a form of IBD, who were taking the new drug Omvoh and achieved clinical remission after 1 ...
Once-daily oral obefazimod met the primary endpoint of clinical remission at 8 weeks in a highly refractory population of ...
A once-daily pill for ulcerative colitis has delivered strong results in a clinical trial, easing symptoms even in patients ...
The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative colitis who weigh ...
Eli Lilly’s ulcerative colitis (UC) treatment, Omvoh (mirikizumab), has shown sustained positive outcomes in patients with ...
The Food and Drug Administration (FDA) has expanded the approval of Simponi ® (golimumab) to include pediatric patients weighing at least 15kg with moderate to severely active ulcerative colitis (UC).
Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition.
Everyday Health on MSN
How to Protect Against Blood Clots if You Have Ulcerative Colitis
People with inflammatory bowel disease, like ulcerative colitis, are 2 to 3 times more likely to develop blood clots than ...
Everyday Health on MSN
Ulcerative Colitis Can Raise Your Risk of Cancer. Here’s What to Know — and Do — About It
Ulcerative colitis and colorectal cancer have a connection, but you can lower your risk of the latter through regular cancer ...
Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ...
New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 ...
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback